依折麦布治疗非酒精性脂肪肝患者的疗效观察

肝脏 ›› 2023, Vol. 28 ›› Issue (10): 1219-1221.

依折麦布治疗非酒精性脂肪肝患者的疗效观察

沈国俊, 黄丽芳, 何翠霞, 黄洁, 曾刚, 黎明

332000 九江市第三人民医院肝病科(沈国俊、黄丽芳、曾刚、黎明),超声科(何翠霞),检验科(黄洁)

收稿日期:2023-06-28 出版日期:2023-10-31 发布日期:2023-12-06
通讯作者: 沈国俊,Email:gjshen@126.com
基金资助:
江西省卫生健康委科技计划普通科技计划(SKJP220211276)

Clinical effects of ezetimibe on the treatment of patients with nonalcoholic fatty liver disease

SHEN Guo-jun, HUANG Li-fang, HE Cui-xia, HUANG Jie, ZENG Gang, LI Ming

Hepatology Unit, the Third People′s Hospital of Jiujiang City, Jiangxi 33200, China

Received:2023-06-28 Online:2023-10-31 Published:2023-12-06
Contact: SHEN Guo-jun, Email: gjshen@126.com

摘要/Abstract

摘要： 目的观察依折麦布治疗非酒精性脂肪肝患者的临床疗效。方法选取2020年4月至2021年10月在九江市第三人医院诊治的56例非酒精性脂肪肝患者,随机分为试验组和对照组,试验组在对照组用药基础上加用依折麦布辅助强化调脂,连续治疗48周。比较两组患者治疗前后临床疗效、血清生化指标和肝脏硬度值的差异。结果治疗48周后,试验组临床总有效率为92.85%(26/28),优于对照组的67.85%(19/28),差异有统计学意义(χ²=5.543,P=0.019)。治疗后试验组血清ALT、AST、γ-GT、TC、TG、LDL-C指标均低于对照组(P<0.05),试验组肝脏硬度值为(6.21±0.99)kPa,低于对照组的(6.79±1.05)kPa,差异有统计学意义(t=-2.109,P=0.040)。结论依折麦布通过调控胆固醇代谢,可改善肝酶指标和肝脏纤维化程度,提高非酒精性脂肪肝患者的临床疗效。

关键词: 依折麦布, 非酒精性脂肪肝, 临床疗效

Abstract: Objective To evaluate the clinic efficacy of ezetimibe in treating patients with nonalcoholic fatty liver disease(NAFLD). Methods From April 2020 to october 2021,56 patients with NAFLD were selected and randomly divided into experimental group and control group. The experimental group was given ezetimibe in addition to the treatment received by the control group, in order to regualte cholesterol metabolism. The treatment course lasted 48 weeks. Clinical effficacy, serum biochemical indicators, and liver stiffness values were observed and compared before and after the treatment. Results After 48 weeks of treatment, the total curative effects in the experimental group and control groups were 92.85% and 67.85%, respectively. The difference was statistically significant (P< 0.05). The levels of ALT, AST, γ-GT, TC, TG, LDL-C in the experimental group were lower than those in the control group, with the differences being statistically significant (P<0.05). The liver stiffness value of the experimental group was lower than that of the control group after treatment, showing a significant difference between the two groups (6.21±0.99 kPa vs. 6.79±1.05 kPa, P<0.05). Conclusion Ezetimibe, by regulating cholesterol metabolism, can enhance liver function indices and reduce liver stiffness, thereby improving the clinical outcomes for patients with NAFLD.

Key words: Ezetimibe, Nonalcoholic fatty liver disease, Clinic effect

沈国俊, 黄丽芳, 何翠霞, 黄洁, 曾刚, 黎明. 依折麦布治疗非酒精性脂肪肝患者的疗效观察[J]. 肝脏, 2023, 28(10): 1219-1221.

SHEN Guo-jun, HUANG Li-fang, HE Cui-xia, HUANG Jie, ZENG Gang, LI Ming. Clinical effects of ezetimibe on the treatment of patients with nonalcoholic fatty liver disease[J]. Chinese Hepatolgy, 2023, 28(10): 1219-1221.

[1]	张翔, 李莹莹, 汤青, 李伟, 孙立柱. CD8⁺ T淋巴细胞水平对晚期肝细胞癌患者免疫治疗疗效的评估价值[J]. 肝脏, 2023, 28(9): 1084-1087.
[2]	栗雯霏, 张捷, 栗建辉. 影像技术对非酒精性脂肪肝的评价[J]. 肝脏, 2023, 28(7): 875-880.
[3]	吕冠海, 陈瑞文, 魏强. ¹²⁵I粒子条胆道腔内放射联合胆道支架植入术治疗恶性梗阻性黄疸[J]. 肝脏, 2023, 28(5): 581-584.
[4]	汪洋, 徐震, 王正, 潘智. ERCP与LBEPS分别联合LC治疗胆囊合并胆总管结石临床疗效比较[J]. 肝脏, 2023, 28(1): 108-111.
[5]	吴小溪, 汪涛, 杜晟楠, 高静静, 蒋元烨, 曹勤. 等热量低碳水化合物高蛋白饮食对非酒精性脂肪肝的干预作用[J]. 肝脏, 2022, 27(6): 688-692.
[6]	王铁钢, 李小明, 朱丹阳. 不同肝组织学特征非肥胖型NAFLD患者磁共振质子密度脂肪分数表现[J]. 肝脏, 2022, 27(5): 573-575.
[7]	任天羿, 范建高. 2021慢性肝病临床研究重大进展回顾[J]. 肝脏, 2022, 27(2): 133-136.
[8]	冯丹妮, 张达利, 贺希, 张晓峰, 牛晓峰, 李志杰, 李丽昕, 刘佳, 庄云龙, 刘振文, 王洪波. 肝移植术后新发非酒精性脂肪肝的危险因素[J]. 肝脏, 2022, 27(1): 95-97.
[9]	薛芮, 范建高. FXR激动剂治疗非酒精性脂肪性肝炎的现状及展望[J]. 肝脏, 2021, 26(8): 835-837.
[10]	张均维, 黄旭东, 蔡弟, 王桂浩. 巨大肝血管瘤患者临床特征及不同介入栓塞材料的价值观察[J]. 肝脏, 2021, 26(7): 788-791.
[11]	辜雪莲, 李俊峰, 毛小荣. 肠道菌群在非酒精性脂肪性肝病中的研究进展[J]. 肝脏, 2021, 26(12): 1418-1420.
[12]	高兰, 刘海蔚, 林璐, 陈开宁. 利拉鲁肽注射液对2型糖尿病合并非酒精性脂肪肝患者内质网应激的影响及其疗效分析[J]. 肝脏, 2020, 25(9): 972-974.
[13]	张进, 张海. FibroScan技术联合血清骨钙素在绝经后女性非酒精性脂肪性肝病患者中的应用[J]. 肝脏, 2020, 25(9): 975-977.
[14]	张黎雯, 任明星, 薛国昌, 沈琳娜, 夏雪霞, 宋月娟, 夏欢. 肠道菌群失调对肥胖儿童非酒精性脂肪肝发生的影响[J]. 肝脏, 2020, 25(7): 755-758.
[15]	张彬, 张立新, 马婷婷, 苗江虎, 王涛. 2型糖尿病患者血清甲状腺激素水平变化及其与非酒精性脂肪肝的关系[J]. 肝脏, 2020, 25(5): 519-521.